Clinical Trial Search

Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…

Primary: Change in Salivary Progesterone Level — 237.86; 97.87 pg/ml

Primary: Negative Affect — 2.91; 2.47 units — p=.62

Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale

Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87

Primary: Mean Length of Hospital Stay — 44.91; 50.50 hours

Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants

Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine

Primary: Easing of Withdrawal Symptoms as Measured by the Withdrawal Assessment Tool (WAT-1) — 3.0; 3.0 Score on a scale

Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001

Primary: Subjective Opioid Withdrawal Scale Score (SOWS) — 16; 4; 24 units on a scale

Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…

Primary: Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour — 9; 19 Participants

Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale

Primary: Buprenorphine Pharmacokinetics

Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…

Primary: Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6) — -1.25; -0.36 opioid-positive urine — p=.42

Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale

Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale

Primary: Change in Withdrawal Symptoms With Placebo and With Ondansetron — -22.08; -42.71 Percent change

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…

Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — -10.4; -10.0; -10.1; -9.8 score on a scale

Primary: Participant Acceptability of the Interventions — 1; 0 Participants

Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours

Primary: Participants With Withdrawal-Emergent Adverse Events — 9; 13 Participants

Primary: Peak SOWS Scores at Baseline and Over Time — 3.6; 5.2; 6.0; 4.7 score on a scale

Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events

Primary: Retention in Treatment — 28 Participants — p=0.0021

Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64